€41.40
0.00% day before yesterday
Xetra, Dec 06, 05:36 pm CET
ISIN
DE0005227201
Symbol
BIO
Index
Sector

Biotest Stock price

€41.40
-0.20 0.48% 1M
+0.20 0.49% 6M
-1.20 2.82% YTD
-1.20 2.82% 1Y
-1.80 4.17% 3Y
+21.30 105.97% 5Y
-44.35 51.72% 10Y
Xetra, Closing price Fri, Dec 06 2024
+0.00 0.00%
ISIN
DE0005227201
Symbol
BIO
Index
Sector

Key metrics

Market capitalization €1.64b
Enterprise Value €2.23b
P/E (TTM) P/E ratio 23.92
EV/Sales (TTM) EV/Sales 3.15
P/S ratio (TTM) P/S ratio 2.32
P/B ratio (TTM) P/B ratio 3.11
Revenue growth (TTM) Revenue growth 7.86%
Revenue (TTM) Revenue €707.00m
EBIT (operating result TTM) EBIT €90.90m
Cash position €24.70m
EPS (TTM) EPS €1.73
Show more

Is Biotest a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.

Biotest Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Biotest:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Biotest:

Hold
100%

Financial data from Biotest

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
707 707
8% 8%
100%
- Direct Costs 467 467
17% 17%
66%
240 240
6% 6%
34%
- Selling and Administrative Expenses 81 81
2% 2%
12%
- Research and Development Expense 68 68
21% 21%
10%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 91 91
22% 22%
13%
Net Profit 69 69
25% 25%
10%

In millions EUR.

Don't miss a Thing! We will send you all news about Biotest directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,426
Founded 1946
Website www.biotest.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today